This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish (read more).


$20 Million Expansion of Biotech Technologies Including Advanced Injectable Delivery Forms

Demand for Biotech packaging drives significant PCI investment at multiple locations world wide

PCI is pleased to announce a momentous investment in support of biologic medicines and advanced injectable delivery forms, totaling more than $20 million. We will add expanded Biotech clinical and commercial packaging and release testing capability at our Center of Excellence in Philadelphia, as well as expanded Cold Chain capacity at numerous global locations to further support our existing Biotech infrastructure.

This latest investment will include capacity expansion for cutting edge technologies for the labeling and assembly of state-of-the-art safety syringes, autoinjector and pen devices with integrated high speed cartoning, in-line serialization, as well as furthering its expansive onsite Cold Chain storage. PCI’s injectable delivery form capabilities include ampoules, vials, cartridges and standard prefilled syringes, as well as advanced safety syringes, autoinjectors and pen devices with services including both simple and complex kitting for clinical and commercial applications. In handling biologic medicines, We maintain a comprehensive Cold Chain and Ultra Cold Chain portfolio with temperature ranges from refrigerated 2-8°C, frozen -20°C, -40°C, -80°C and cryogenic temperatures of -196°C for Advanced Medicinal Therapeutic Products (ATMP), including cell and gene therapy medicines.

I am pleased to share this news regarding our continued investment to support the needs of our biotech customers,” notes Salim Haffar, CEO of PCI. “It’s estimated that close to 40 per cent of all medicines in pipeline development are biologic, and amazing new therapies are being developed and commercialized every day. With the development and commercialization wave of biologic medicines, the market is rapidly evolving. We are proud to be the partner of choice for drug development companies as they look to outsource these specialized requirements for clinical and commercial packaging. These investments demonstrate our commitment to bring lifesaving medicines to patients around the world.

We provide industry leading services for the clinical and commercial packaging of multiple delivery forms such as injectables, topicals, transdermals and solid oral dose Our rich history of supporting these advanced delivery forms spans more than two decades – and includes the introduction of the industry’s first biologic medicines. Our global network for biologics has since grown to include sites based in the United States, United Kingdom, Europe and Australia, providing support for medicines destined to reach more than 100 countries around the world.

January 7, 2019

Expansion of Controlled Substance Storage to Support Blister Packaging Capacity for Opioids

PCI stands ready to support packaging changes brought in by new Opioid legislation PCI Is pleased to announce further investment... View Article

PCI Brexit Communication, 16 January 2019

The UK Parliament voted on 15th January 2019 rejecting the EU/UK Brexit deal and therefore, a number of unknown variables... View Article